Antimicrobial Resistance (AMR)

As the leading global provider of generic antibiotics, Sandoz is committed to improving global access to medicine.  Our parent company Novartis,  one of 130 companies to sign the ‘Davos Declaration’ in January 2016 calling for a collective response to AMR, is also one of 13 companies to sign the subsequent ‘Industry Roadmap’ in September 2016, outlining concrete actions across four areas: access, responsible use, responsible manufacturing and R&D.

We’re equally committed to ensuring the responsible use of medicine. This may mean making some tough business choices as we balance short and long term interests, but we are not alone. Let’s be clear: AMR is a truly global problem, which requires global, multi-stakeholder collaboration.

There are no simple, quick-fix solutions. But with rising political attention and a pledge from industry to play a meaningful role, we have a unique window of  opportunity to take concrete steps to combat this growing global threat. Let’s do the right thing, together.

Latest News:

Nov 20, 2017
Drugs versus bugs: It’s time to talk about antimicrobial resistance
By Rex Clements, Head of Global Franchises at Sandoz.

Nov 13, 2017
Top UK government advisor Lord Jim O’Neill calls on pharmaceutical industry to “think more broadly” about growing global threat of antimicrobial resistance
Lord Jim O’Neill, the author of the UK government-commissioned Review on AMR, has called on the pharmaceutical industry to “think more broadly” about the role it can play in combatting the growing global threat of antimicrobial resistance (AMR).

Related Resources:

Access to Medical Information

Spreading Knowledge, not Resistance (8 min read)

Access to Medicines

Facing Antimicrobial Resistance (7 min read)

Access to Medical Information

Washing hands, saving lives - the surprising health benefits of clean hands (9 min read)

Access to Healthcare

From plant to medicine: How an ancient plant-based remedy became a modern malaria medicine (11 min read)